Treatment of Kynurenin-producing Tumors with AhR Antagonists

Activation of the aryl hydrocarbon receptor (AHR) by environmental xenobiotic toxins has been implicated in a variety of cellular processes such as embryogenesis, transformation, tumorigenesis and inflammation. The TDO-AHR pathway is active in human brain tumors and associated with malignant progression and poor survival. As Kyn is produced during cancer progression and inflammation in the local microenvironment in amounts sufficient for activating the human AHR, these results can be used to develop a specific chemotherapy to manipulate AhR activated signal pathways in susceptible cancer cells. Using this mechanism more treatment opportunities can be used and different tumor types can be treated by AhR related drugs.

Further Information: PDF

Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Lighting up the future

New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…

Researchers crack sugarcane’s complex genetic code

Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….

Evolution of the most powerful ocean current on Earth

The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….

Partners & Sponsors